CRDL

0.86252.29%
AW

Andrew Warwick Hamer

Chief Medical Officer and Head of Research & Development

Dr. Andrew Warwick Hamer, M.D., MB, ChB, serves as Chief Medical Officer at Cardiol Therapeutics Inc. since September 2022 and also serves as Head of Research & Development. Dr. Hamer lead the research and development of the Cardiol Therapeutics's clinical-stage products and will also guide the development of additional novel therapeutics in its pipeline. Dr. Hamer has experience in the global life sciences industry, medical affairs, and cardiology practice. Most recently he served as Executive Director, Global Development-Cardiometabolic at California-based Amgen Inc., where he led the Global Development group for Repatha®, the LDL cholesterol lowering PCSK9 inhibitor evolocumab. As development lead, Dr. Hamer Headed the Repatha® global evidence generation team collaborating with safety, regulatory, health economics, observational research, scientific communications, publications, medical affairs, and clinical operations teams to design and execute several multi-center clinical trials in support of FDA and international regulatory filings. Dr. Hamer served as Vice President of Medical Affairs at Capricor Therapeutics, Inc. from November 2013 to July 30, 2015. Prior to joining the life sciences industry, Dr. Hamer practiced cardiology and internal medicine in New Zealand. His distinguished career in cardiology culminated as Chief Cardiologist at Nelson Hospital, Nelson Marlborough District Health Board, Nelson, while concurrently leading cardiac services nationally in New Zealand. Dr. Hamer completed internal medicine and cardiology training at Green Lane Hospital in Auckland, New Zealand, having completed his Degree in Medicine from Otago University. He also completed a Senior Cardiology Fellowship at the Deaconess Hospital and at Harvard Medical School in Boston. His clinical research training took place at various centres in New Zealand and London, UK, followed by a cardiology fellowship at Deaconess Hospital, Harvard Medical School, Boston. Dr. Hamer has co-authored many high-quality peer-reviewed scientific publications reflecting his considerable experience as a clinical trialist, having served as a Principal or co-investigator for 40 multi-centre clinical trials in therapies for acute coronary syndrome, heart failure, hypertension, cholesterol disorders, atrial fibrillation, and diabetes. Dr. Hamer graduated with a medical degree (MB, ChB) from the University of Otago, New Zealand.

Positions